An interventional study of CBT4CBT-Buprenorphine in Opioid Use Disorder, sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Opioid-Related Disorders by Medical University of South Carolina — 7 open to participants now, 7 under way, none of them phase 3. Opioid-Related Disorders · Medical University of South Carolina.
Among the 15 studies in Opioid-Related Disorders by Medical University of South Carolina, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2026, is one of 8 with no phase, and was the 12th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →7 of the 15 studies in Opioid-Related Disorders by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:
Medical University of South Carolina · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18–45 · Women only
Medical University of South Carolina · Sites in United States
Ages 18+
Medical University of South Carolina · Sites in United States
Ages 18–70
By country, each count listing its studies:
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 230 is above the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 24 across the 15 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Medical University of South Carolina is the lead sponsor of 875 studies on the registry; 165 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 104 (79%) have results posted.
4 of the studies in Opioid-Related Disorders by Medical University of South Carolina that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06157840Medical University of South CarolinaDevelopment of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD | 2026-12-15 |
| NCT07421102Medical University of South CarolinaPilot of Mailing Buprenorphine | 2027-01 |
| NCT07278518Medical University of South CarolinaEvaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine | 2027-02-13 |
| NCT06641115Medical University of South CarolinaIntegrated Treatment for Opioid Use Disorder and PTSD | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 15 studies in Opioid-Related Disorders by Medical University of South Carolina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Problems with social functioning are core to opioid use disorder (OUD), though specific, modifiable social functioning targets and how they relate to OUD treatment outcomes are poorly understood. This study will utilize both data from both patients with OUD and their concerned significant other (CSO) to examine associations between specific social functioning metrics and OUD treatment outcomes. Findings from this study will inform future precision-medicine approaches for people with OUD, a population in significant need of enhanced treatment approaches to combat opioid morbidity and mortality.
Opioid use disorder (OUD) continues to be associated with high rates of morbidity and mortality and has a significant impact on affected individuals, their families, and their communities. Problems related to social functioning are part of OUD criteria and a wealth of research suggests that individuals with OUD may be prone to experiencing isolation, loneliness, lack of social support, and poor conflict resolution and problem-solving skills in interpersonal contexts. Emerging evidence suggests that OUD treatment, particularly behavioral treatments adjunctive to medications for OUD (MOUD), may improve social functioning and that gains in social functioning may have beneficial impacts on OUD recovery; however, the specific social functioning metrics that are associated with positive OUD treatment trajectories are understudied. Further, much of the extant literature has only examined social functioning from the lens of the patient with OUD, even though reports from concerned significant others (CSOs) may have valuable predictive utility. This study seeks to address gaps in the field by examining how affiliative social engagement behaviors, social reward, and social connection change and are associated with positive OUD treatment outcomes among a sample of 115 patient-CSO dyads. The study will combine established ecological momentary assessment (EMA) methods with the use of an innovative smartwatch-based application (i.e., SocialBit) in a single-armed trial to assess both subjective self-reports and objective measurements of social functioning from patients with OUD and a non-substance using CSO. Aim 1 will determine how patient-reported and CSO-reported social behaviors, social reward, and social connection change during OUD treatment; Aim 2 will identify if patient-reported and CSO-reported social behaviors, social reward, and social connection predict MOUD adherence and opioid craving; Exploratory Aim 3 will validate the use of SocialBit for assessing social connection in an OUD treatment sample. There is an urgent need to address how social functioning contributes to OUD and opioid overdose, and to take a "whole person" approach to treatment. Findings have strong potential to inform future precision-medicine approaches focused on the dual targets of OUD and social functioning.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CBT4CBT-Buprenorphine
Behavioral: CBT4CBT-Buprenorphine
CBT4CBT-Buprenorphine is an evidence-based, Internet-delivered cognitive behavioral therapy program for individuals prescribed buprenorphine by a medical provider. It includes eight 30-minute modules.
Affiliative social behaviors
Checklist of 12 items assessing social interaction behaviors (adapted from the Social Behavior Inventory; Moskowitz, 1994), summed, averaged, and ipsatized to assess dominant behavior, submissive behavior, agreeable behavior, and quarrelsome behavior. Higher scores reflect greater frequency of the type of behavior.
Time frame: Week 1 to Week 14
Social reward
1 item assessing how much an individual liked their social interactions (adapted from Geyer, et al., 2018). Higher scores reflect more enjoyment from social interactions.
Time frame: Week 1 to week 14
Social connection
1 item assessing how close an individual felt with others (adapted from Flores et al., 2015). Higher scores reflect greater feelings of closeness.
Time frame: Week 1 to week 14
Medication for opioid use disorder adherence
2 items assessing daily adherence to taking medication for opioid use disorder (response options: yes; no, I took it, but not as prescribed; no, I did not take buprenorphine) and at what dose (in mgs).
Time frame: Week 1 to week 14
Craving
1 item assessing craving for opioids (adapted from Mun et al., 2021; Ellis et al., 2022). Higher scores reflect greater craving.
Time frame: Week 1 to week 14
Plan to share: Yes — Documentation to be made available will include a study protocol, reference to study publication of primary outcomes, data sets, case report forms, a data dictionary, and study-specific notes. Variables in the NIMH Data Archive (NDA) data dictionary will include a description, variable name, variable label, and standard codes for missing values. Coded interview data, scale composites, recodes will be shared.
Supporting information: Study protocol, Clinical study report
Time frame: A NDA Data Submission Agreement will be signed and a NDA Data Expected section will be completed within six months of receipt of the award. Data will be deposited to NDA every six months, according to the NDA submission deadlines. The research community will have access to the full data set approximately 18 months following the end of the study or after the primary paper has been accepted for publication, whichever happens first. Study data deposited will be available to the research community indefinitely.
Access criteria: Data will be findable for the research community through NDA.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Aug 2029, 36 months after the start.
Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 36 months is above that.
Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of South Carolina →